Search

Background and aims: PDN can lead to severe deterioration in quality of life. While published data demonstrate 10kHz SCS provides substantial refractory pain relief and neurologic improvement for PDN patients1, here we report durability of these outcomes. Methods: Prospective, multicenter, RCT to document the impact of 10kHz SCS on PDN. Participants had PDN symptoms ≥12 months (M) , refractory to medications, lower limb pain intensity ≥5cm (0-10cm visual analog scale [VAS]) , and hemoglobin A1c ≤10%. Patients (N=216) were allocated 1:1 to 10kHz SCS (Nevro Corp.) plus conventional medical management (CMM) or CMM alone with optional crossover at 6 M. Results: The 10kHz SCS patients maintained substantial pain relief from 3 M, averaging 81.9% (95%CI 77.3 - 86.5) decrease at 24 M. At 6 M follow up, 0% of 10kHz SCS participants but 93% of eligible CMM patients elected to crossover. After SCS, both groups reported similar significant improvements in pain, sleep disturbance, and in pain interference with mood and daily activities (see Figure 1) . There were no stimulation-related neurological deficits and 6 total explants (3.9%) , 5 due to procedure-related infections and 1 as a precaution for endocarditis. Conclusions: The largest RCT to date of SCS management of PDN demonstrates safety, durable pain relief and neurologic improvement over 24 months with 10 kHz SCS. Disclosure E. Petersen: Consultant; Abbott, Biotronik, Boston Scientific Corporation, Medtronic, Nalu, Neuros Medical, Nevro Corp., Presidio, Saluda Medical, Vertos Medical Inc., Research Support; Medtronic, Neuros Medical, Nevro Corp., ReNeuron, Saluda Medical, SPR, Stock/Shareholder; neuro42, SynerFuse. C. Yu: Consultant; Boston Scientific Corporation, Nevro Corp., Research Support; Nevro Corp. A. Nairizi: Consultant; Nevro Corp. D. G. Patterson: Advisory Panel; AIS, Consultant; Pajunk Medical, Other Relationship; Abbott, CornerLoc, Flowonix, Saluda Medical, Vertiflex, Vertos, Vivex Biologics, Research Support; Nevro Corp., Speaker’s Bureau; AbbVie Inc., Lundbeck. V. Galan: None. R. Bundschu: None. N. Mehta: Consultant; Nevro Corp. D. Sayed: Consultant; Nevro Corp. D. Dibenedetto: None. K. A. Sethi: None. P. W. Wu: None. T. G. Stauss: None. C. Argoff: Consultant; Nevro Corp. C. E. Nasr: Advisory Panel; Exelixis, Horizon Therapeutics plc, Neurogastrx, Nevro Corp., Research Support; Siemens. R. Taylor: Consultant; Nevro Corp. D. L. Caraway: Employee; Nevro Corp. J. A. Scowcroft: Research Support; Boston Scientific Corporation, Nevro Corp., Saluda Medical. E. Brooks: Employee; Nevro Corp., Presidio Medical, Stock/Shareholder; Nevro Corp., Presidio Medical. J. L. White: Advisory Panel; Nevro Corp. S. M. Sills: None. K. Amirdelfan: Consultant; Nevro Corp. M. Guirguis: Advisory Panel; Averitas Pharma, Inc., Boston Scientific Corporation, Pacira BioSciences, Inc., Consultant; Avanos Medical, Inc., Nevro Corp., OmniaMed, Saluda Medical. J. Xu: None. Funding Nevro Corp.

BACKGROUND. This report presents weighted average estimates of the prevalence of periodontitis in the adult US population during the 6 years 2009–2014 and highlights key findings of a national periodontitis surveillance project. METHODS. Estimates were derived for dentate adults 30 years or older from the civilian noninstitutionalized population whose periodontitis status was assessed by means of a full-mouth periodontal examination at 6 sites per tooth on all non–third molar teeth. Results are reported according to a standard format by applying the Centers for Disease Control and Prevention/American Academy of Periodontology periodontitis case definitions for surveillance, as well as various thresholds of clinical attachment loss and periodontal probing depth. RESULTS. An estimated 42% of dentate US adults 30 years or older had periodontitis, with 7.8% having severe periodontitis. Overall, 3.3% of all periodontally probed sites (9.1% of all teeth) had periodontal probing depth of 4 millimeters or greater, and 19.0% of sites (37.1% of teeth) had clinical attachment loss of 3 mm or greater. Severe periodontitis was most prevalent among adults 65 years or older, Mexican Americans, non-Hispanic blacks, and smokers. CONCLUSIONS. This nationally representative study shows that periodontitis is a highly prevalent oral disease among US adults. PRACTICAL IMPLICATIONS. Dental practitioners should be aware of the high prevalence of periodontitis in US adults and may provide preventive care and counselling for periodontitis. General dentists who encounter patients with periodontitis may refer these patients to see a periodontist for specialty care.